The Alzheimer’s Foundation of America (AFA) will begin its annual trek across the United States next month to raise disease awareness, promote early detection, and connect communities through education. Now in its fourth year, the 2020 Educating America Tour will make its first stop in Albuquerque, New…
The U.S. Food and Drug Administration (FDA) has agreed to review a new drug application (NDA) for Adlarity — Corium’s once-weekly transdermal (skin) patch delivering donepezil — to treat dementia in Alzheimer’s disease. The FDA’s decision on whether or not to approve Adlarity is expected by July…
Soybean oil, an increasingly common cooking oil, especially in the United States, can cause changes in the brain that could be linked to diabetes, inflammation, and brain disorders, an early study in mice suggests. This oil, a type of polyunsaturated fat, is used to fry fast foods, added to…
Certain patterns of brain activity can predict early on the probability of cognitive decline in young mice at high genetic risk of developing Alzheimer’s disease, a study has found. The findings, “Early Hippocampal Sharp-Wave Ripple Deficits Predict Later Learning and Memory Impairments in an Alzheimer’s Disease…
Changes in the way older people handle their finances could be a sign that they are developing Alzheimer’s or another form of dementia, studies suggest. An associate neurology professor in Oregon is taking the research a step further by trying to determine the types of behavioral changes that should…
The levels of circular RNAs in the brains of patients with Alzheimer’s disease are linked to several traits and clinical measures of disease severity, a study shows. Because these circular RNAs also can be detected in cerebrospinal fluid and blood, they may hold the potential to be used as biomarkers…
When we think about Alzheimer’s disease, we often focus solely on the patient. However, the health of the caregiver is important as well. A caregiver is someone who attends to a patient’s needs and wants on a…
A new screening assay has identified small molecules capable of protecting brain mitochondria from stress conditions that commonly occur in Alzheimer’s and other neurodegenerative diseases. These preclinical results in mice support the therapeutic potential of these newly discovered compounds. The study, “Neuron-based high-content assay and screen for CNS…
A protein involved in ovarian cancer, known as OCIAD1, contributes to the neurodegeneration seen in Alzheimer’s disease, and may be a more fitting treatment target than beta-amyloid, a protein long linked to this disease, a study suggests. Specifically, elevated levels of the OCIAD1 protein affect the workings of a small organelle…
Biogen is acquiring from Pfizer investigational therapy PF-05251749, a small molecule being developed to treat sundowning in Alzheimer’s disease and irregular sleep wake rhythm disorder (ISWRD) in Parkinson’s disease. The company plans to begin a Phase 1b clinical trial by the end of this year,…
Get regular updates to your inbox.